RCT of 55 participants with suspected at-risk MASH selected by non-invasive tests: semaglutide 2.4 mg weekly reduced FAST score more than placebo at 52 weeks (-0.28 vs -0.12; p=0.002), with more ≥5% weight loss (64% vs 8.3%); GI adverse events did not differ significantly.
RCTn = 55
Ajmera et al. Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)